The Healius Ltd (ASX: HLS) share price is on course to end the week in the red.
At the time of writing, the healthcare company’s shares are down 2% to $5.17.
Why is the Healius share price falling?
Investors have been selling down the Healius share price today after it announced an agreement to acquire the entire issued capital of Agilex. It is one of Australia’s leading bioanalytical laboratories.
According to the release, the transaction values Agilex at an enterprise value of $301.3 million.
The release explains that Agilex has a high margin and capital-light business model with immediate and long-term growth potential. This will be enhanced by Healius’ experience operating laboratory businesses and by increased financial capacity to support the delivery of the growth strategy.
Management sees Agilex as a long-term strategic acquisition that provides the company with a platform for growth into the global clinical trials sector and a structurally attractive, higher growth, higher margin adjacency.
Agilex is expected to generate revenue and EBITDA in the range of $36-40 million and $14-16 million, respectively, in calendar year 2022, with strong future earnings growth anticipated. Judging by the Healius share price reaction, investors may believe this makes the transaction value a little on the rich side.
Nevertheless, the acquisition is expected to deliver low single digit earnings per share accretion in the first full year of ownership.
Healius’ Managing Director and CEO, Dr Malcolm Parmenter, said: “The acquisition of Agilex is an exciting opportunity for Healius. Agilex has a talented scientific team with state-of-the-art laboratories and culturally complements Healius. It’s a logical entry point for Healius into the attractive global bioanalytical laboratory services market, and one in which Australia and Agilex, in particular, is wellplaced to service.”
“We see Agilex as a long-term strategic acquisition that adds a global orientation to the Healius network. A business that is growing fast, in a fast-growing market. Agilex is well placed to realise a material step-change in earnings growth over the near to medium-term,” he added.
The post Healius (ASX:HLS) share price falls despite $300m acquisition appeared first on The Motley Fool Australia.
Should you invest $1,000 in Healius right now?
Before you consider Healius, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Healius wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
More reading
- 3 fantastic ASX growth shares to buy right now
- 2 excellent ASX 200 dividend shares to buy in December
- Why Domino’s, Healius, Kogan, and Vulcan shares are pushing higher
- ASX 200 healthcare shares jump amid Omicron fears
- ASX 200 (ASX:XJO) midday update: Omicron hits Flight Centre, Domino’s jumps
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3J03KfQ
Leave a Reply